Investigational drug · Phase 3
SCTA01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for COVID-19, SARS-CoV-2.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 29, 2021 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "SCTA01"
First trial start
2021
Mar 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCTA01", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19
- SARS-CoV-2
Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "SCTA01" as an intervention, largest first.
- To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19Pivotal-lookingNot yet recruiting
Sinocelltech Ltd.Industry
NCT04709328 · 690 participants (planned) · Start Mar 28, 2021 · Primary completion Jan 1, 2022
Drug: SCTA01 · For: COVID-19; SARS-CoV-2
- The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive CarePivotal-lookingStatus unknown
Sinocelltech Ltd.Industry
NCT04683328 · 560 participants (planned) · Start Feb 25, 2021 · Primary completion May 25, 2021
Drug: SCTA01; SCTA01 Placebo · For: Covid19
- The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19Pivotal-lookingTerminated
Sinocelltech Ltd.Industry
NCT04644185 · 102 participants · Start Mar 27, 2021 · Primary completion Dec 29, 2021
Drug: SCTA01 · For: Covid19
Sites: Somers Point, New Jersey; Buenos Aires, Argentina; Uberlândia, Brazil · 7 sites in all
Sinocelltech Ltd.Industry
NCT04483375 · 33 participants · Start Jul 24, 2020 · Primary completion Nov 17, 2020
Drug: SCTA01 · For: Coronavirus Disease 2019(COVID-19)
Sites: Beijing, China
Sinocelltech Ltd.Industry
NCT05156645 · 0 participants · Start Jan 15, 2022 · Primary completion Dec 1, 2022
Drug: SCTA01 and SCTA01C; Placebo · For: COVID-19
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial.
Diaz J, Fonseca A, Yan L, et al. · Contemp Clin Trials Commun 2025
- Fc-Modified Antibody in Hospitalized Severe COVID-19 Patients.
Dal-Pizzol F, Lobo SM, Lucasti C, et al. · Vaccines (Basel) 2025
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
Li Y, Qi L, Bai H, et al. · Antimicrob Agents Chemother 2021
- Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2.
Baral PK, Yin J, James MNG · Int J Biol Macromol 2021
- COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19.
Yang L, Liu W, Yu X, et al. · Antib Ther 2020
Also in development for COVID-19
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- VYD2311Phase 32 trials
Invivyd, Inc. · Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine
- DAS181Phase 31 trial
Ansun Biopharma, Inc. · Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised
- VYD222pemivibartPhase 31 trial
Invivyd, Inc. · COVID-19, SARS-CoV-2
- VYD2311-MDPhase 31 trial
Invivyd, Inc. · COVID-19
- VYD2311-SDPhase 31 trial
Invivyd, Inc. · COVID-19
- CVXGACVXGA50, PIV5-SARS CoV-2Phase 22 trials
CyanVac LLC · COVID-19
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.